Navigation Links
PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
Date:11/7/2011

BOSTON, Nov. 7, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Lazard Capital Markets Healthcare Conference in New York.  Josef von Rickenbach, Chairman and Chief Executive Officer will be making a presentation on PAREXEL at 11:30 a.m. ET on Tuesday, November 15, 2011.

PAREXEL will also be presenting at the Citi Small/Mid Cap Conference in Las Vegas.  James Winschel, Sr. Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 10:55 a.m. PT on Tuesday, November 15, 2011.

A live webcast of the Lazard Capital presentation will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until February 15, 2012.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries.  Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc.  All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contact:
Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@PAREXEL.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
2. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
3. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
4. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
5. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
6. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
7. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
8. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
9. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
10. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
11. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Thank you ... Diego on February 8-10. , This event was exclusive to providers and offered ... , The meeting took place at the Manchester Grand Hyatt where attendees gathered for ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Bacteria and fungi are probably not the first ... bad. In fact, including the right microorganisms in your diet can actually improve health outcomes. ... , This is the topic of a new peer-reviewed paper led by ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... site attention and engagement over the household brands of Top-20 pharma by optimizing ... discuss how partnering with the right outsourcing payments provider can provide the technology, ...
(Date:3/27/2017)... Reston, VA (PRWEB) , ... March 27, 2017 ... ... mobile application containerization, today announced it will co-exhibit with technology partners LG Business ... held at the Marriott Metro Center in Washington D.C., will provide education and ...
Breaking Medicine News(10 mins):